Dear All, There are more details yet to come, but the EU Council (“the Council”) and the EU Parliament (EP) yesterday announced an agreement on the update to the EU General Pharmaceutical Legislation that includes transferable exclusivity vouchers (TEVs or TEEVs, depending on your preferred abbreviation). Here’s the key text from the EP’s press release:
Dear All (and with thanks to Frédéric Peyrane for leading on this newsletter): You will know that we eagerly watching the work in the EU on implementing a set of pull incentives based on use of ‘transferable data exclusivity voucher’ (TEV), also referred to as a ‘transferable exclusivity extension voucher’ (TEEV). In brief, the concept is that a TEEV
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), In the wake of the Sep 2024 UNGA HLM on AMR (UN General Assembly High-Level Meeting on AMR), it has been encouraging to see the continued discussion around Push and Pull incentives for antibacterial innovation and access (see the AMR.Solutions post-UNGA webpage for
Dear All, As a follow-on to the global commitments made during the 2024 UN General Assembly High-Level Meeting on AMR (UNGA 2024 HLM AMR), the Global Future Council on AMR of the World Economic Forum (WEF) authored the 2025 Davos Compact on AMR with review by the Quadripartite Joint Secretariate on AMR as a way for organizations to
Dear All, With thanks to alert reader Liam Sharkey, a post-doc in Melbourne, for the heads-up on this topic, I am very pleased to see the 17 June 2025 report from Australia entitled “Fighting Superbugs: A Subscription-Style Reimbursement Mechanism to Boost Australia’s Arsenal of Antimicrobial Medicines.” This paper is the output from a Nov 2024 roundtable in Canberra
Dear All, The 27 Sep 2024 newsletter (“Without action, AMR costs go from $66b to $159b/yr by 2050”) reviewed a report by Anthony McDonnell and a team led by the Center for Global Development in which they created economic estimates of the costs/values of action (and inaction) through 2050, based on 5 possible action/ inaction scenarios.
Dear All (and with thanks to Damiano for taking the lead on this newsletter), We wrote previously in (i) the 7 Dec 2023 newsletter (“How Italy should Push and Pull: New report as Italy takes the 2024 G7 chair”), (ii) the 17 Oct 2024 newsletter (“Italy funds CARB-X and announces pull incentive!”), and finally (iii) the 9 Jan
Dear All, Referring back to the actions planned following the 2024 UNGA HLM on AMR (UN General Assembly High-Level Meeting on AMR; 1 Oct 2024 newsletter and our dedicated UNGA 2024 webpage), you will hopefully recall the commitment to create an Independent Panel on Evidence for Action against AMR (IPEA). The broad idea is the
Dear All (Deeply wonkish alert! Settle in! Great stuff here!): For today, we have a deep dive into the ongoing work in the EU to develop a set of realistic pull incentives using our best understanding to date of realistic choices. If the idea of Pull (and Push) is new to you, please check out
Dear All, I was recently asked about a ready summary of the current state of play of Pull incentives around the globe. In response, here are two related resources: First, WHO and the Global AMR R&D Hub jointly author an update on the state of incentives for R&D. Their most current report is dated 14 Oct